The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.7M data for 1.2M Compounds and 9.0K Targets. Of those, 1,253K data for 577K Compounds and 4.4K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.


If BindingDB is of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

12 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

Article Title
Dihydropyrimidine calcium channel blockers. 2. 3-substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines.EBI
Squibb Institute for Medical Research
Dimeric 1,4-dihydropyridines as calcium channel antagonists.EBI
State University of New York
Crystal structures and pharmacologic activities of 1,4-dihydropyridine calcium channel antagonists of the isobutyl methyl 2,6-dimethyl-4-(substituted phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (nisoldipine) series.EBI
University of Oslo
Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639.EBI
AbbVie Inc
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.EBI
University of Oxford
From hit to lead. Analyzing structure-profile relationships.EBI
Universities of Lille
Phenyl-glycinol based NK1 receptor antagonists — towards the minimum pharmacophoreEBI
New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine HEBI
Universit£ Bourgogne Franche-Comt£
The discovery and optimization of benzimidazoles as selective NaEBI
Pfizer Inc.
MICE models: superior to the HERG model in predicting Torsade de Pointes.EBI
ChanTest Corporation
Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties.EBI
Emory University
4-Isoxazolyl-1,4-dihydropyridines: biological, theoretical, and structural studies.EBI
State University of New York